Piper Sandler Maintains Overweight on Biomarin Pharmaceutical, Raises Price Target to $122
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler has maintained an Overweight rating on Biomarin Pharmaceutical and raised its price target from $107 to $122, indicating a positive outlook for the company's stock.
September 05, 2024 | 1:45 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Piper Sandler has maintained an Overweight rating on Biomarin Pharmaceutical and increased the price target from $107 to $122, suggesting a positive short-term outlook for the stock.
The increase in the price target from $107 to $122 by Piper Sandler, along with the maintained Overweight rating, indicates a strong positive sentiment from the analyst. This is likely to boost investor confidence and could lead to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100